FARMERS & MERCHANTS TRUST Co OF LONG BEACH Sells 11,075 Shares of AbbVie Inc. $ABBV

FARMERS & MERCHANTS TRUST Co OF LONG BEACH reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 64.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 6,027 shares of the company’s stock after selling 11,075 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in AbbVie were worth $1,395,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ABBV. Conning Inc. boosted its position in shares of AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares in the last quarter. Diversified Trust Co raised its stake in AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after buying an additional 10,891 shares during the period. Dohj LLC boosted its holdings in AbbVie by 41.8% in the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after acquiring an additional 1,335 shares in the last quarter. Permanent Capital Management LP bought a new position in AbbVie in the third quarter worth approximately $720,000. Finally, Railway Pension Investments Ltd grew its stake in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after acquiring an additional 211,800 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a three‑year drug‑pricing agreement with the White House that grants exemptions from certain tariffs and future pricing mandates in exchange for lower Medicaid pricing and a pledge to invest $100 billion in U.S. R&D and capital over the next decade — market sees tariff relief and large domestic investment as net positives for cash flow visibility and political risk reduction. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to an exclusive global licensing/partnering deal for RC148 (a PD‑1/VEGF bispecific) with RemeGen — up to ~$5.6B — boosting its oncology pipeline and giving upside to future sales if the asset progresses. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: Operational and manufacturing expansion: AbbVie is acquiring an Arizona drug‑delivery/manufacturing facility and the SmartDose on‑body system rights from West Pharma, and announced a $175M investment in an Arizona drug‑device plant — these moves support supply security, onshoring and next‑gen product delivery capacity. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Regulatory engagement: AbbVie (with peers) is leading calls for the FDA to update post‑approval change rules — potential long‑run operational implications, but not an immediate earnings driver. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Neutral Sentiment: Clinical pipeline progress: Phase‑2 readout/trial completion for ABBV‑932 (bipolar depression) was reported — positive for pipeline optionality but early stage and uncertain commercial timing. AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion
• Neutral Sentiment: Analyst / retail attention: Several bullish analyst pieces and increased investor searches highlight AbbVie’s dividend and value characteristics — supportive sentiment but not a direct fundamental change. Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
• Negative Sentiment: Revenue and margin risk from price concessions: the White House pact requires lower Medicaid pricing and expanded affordable patient offerings, which could blunt near‑term revenue/margin growth for products used widely in public programs — investors will watch guidance and product‑level impact. Abbvie, US reach agreement to cut drug prices

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of research reports. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a research report on Tuesday. Citigroup decreased their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. JPMorgan Chase & Co. upped their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research note on Tuesday, November 4th. Finally, Morgan Stanley lifted their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Trading Up 0.2%

Shares of NYSE:ABBV opened at $220.51 on Wednesday. The stock has a market cap of $389.72 billion, a PE ratio of 167.05, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The stock’s fifty day simple moving average is $226.84 and its two-hundred day simple moving average is $216.04. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the prior year, the business posted $3.00 EPS. The business’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.